Biodegradable double-targeted PTX-mPEG-PLGA nanoparticles for ultrasound contrast enhanced imaging and antitumor therapy in vitro

Ma, Jing; Shen, Ming; Xu, Chi; Sun, Ying; Duan, You Rong; Du, Lian Fang

doi:10.18632/oncotarget.13243

Cited by 18 publications

(9 citation statements)

References 22 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been many studies on nanobubbles as drug carriers, but low drug loading efficiency is still a common problem. The drug loading efficiency of some hydrophobic drugs, such as paclitaxel (PTX) and doxorubicin (DOX), was ranged from 2.666 ± 0.092% to 6.69 ± 0.69% in the literature, [21][22][23][24][25] and the drug loading efficiency of G250-TNBs in this study was 5.23% ± 0.91%. On the one hand, the low efficiency of drug loading may be due to the fact that the nanobubbles are vesicles with the perfluoropropane gas wrapped in the lipid envelope, and TEM is a hydrophobic drug that encapsulates only in the lipid envelope.…”

Section: Discussionmentioning

confidence: 71%

G250 Antigen-Targeting Drug-Loaded Nanobubbles Combined with Ultrasound Targeted Nanobubble Destruction: A Potential Novel Treatment for Renal Cell Carcinoma

Wang

et al. 2020

IJN

View full text Add to dashboard Cite

Purpose: We intended to design G250 antigen-targeting temsirolimus-loaded nanobubbles (G250-TNBs) based on the targeted drug delivery system and to combine G250-TNBs with ultrasound targeted nanobubble destruction (UTND) to achieve a synergistic treatment for renal cell carcinoma (RCC). Methods: The filming-rehydration method was combined with mechanical shock and electrostatic interactions to prepare temsirolimus-loaded nanobubbles (TNBs). G250-TNBs were prepared by attaching anti-G250 nanobodies to the surface of TNBs using the biotinstreptavidin-bridge method. The ability of G250-TNBs to target the G250 antigen of RCC cells and the synergistic efficacy of G250-TNBs and UTND in the treatment of RCC were assessed. Results: The average diameter of the prepared G250-TNBs was 368.7 ± 43.4 nm, the encapsulation efficiency was 68.59% ± 5.43%, and the loading efficiency was 5.23% ± 0.91%. In vitro experiments showed that the affinity of G250-TNBs to the human RCC 786-O cells was significantly higher than that of TNBs (P <0.05), and the inhibitory effect on 786-O cell proliferation and the induction of 786-O cell apoptosis was significantly enhanced in the group treated with G250-TNBs and UTND (G250-TNBs+ UTND group) compared with the other groups (P <0.05). In a nude mouse xenograft model, compared with TNBs, G250-TNBs could target the transplanted tumors and thus significantly enhance the ultrasound imaging of the tumors. Compared with all other groups, the G250-TNBs+UTND group exhibited a significantly lower tumor volume, a higher tumor growth inhibition rate, and a higher apoptosis index (P <0.05). Conclusion: The combined G250-TNBs and UTND treatment can deliver anti-tumor drugs to local areas of RCC, increase the local effective drug concentration, and enhance antitumor efficacy, thus providing a potential novel method for targeted therapy of RCC.

show abstract

Section: Discussionmentioning

confidence: 71%

G250 Antigen-Targeting Drug-Loaded Nanobubbles Combined with Ultrasound Targeted Nanobubble Destruction: A Potential Novel Treatment for Renal Cell Carcinoma

Wang

et al. 2020

IJN

View full text Add to dashboard Cite

show abstract

“…The use of gas-filled nanobubbles (NBs) constructed from poly (lactide-co-glycolic acid; PLGA), which is a biodegradable copolymer, improves US signals [ 61 ]. Therefore, it has been popularized as contrast agent for CT imaging.…”

Section: In Vivo Imagingmentioning

confidence: 99%

Targeted Molecular Imaging Using Aptamers in Cancer

Yoon

Rossi

2018

Pharmaceuticals

View full text Add to dashboard Cite

Imaging is not only seeing, but also believing. For targeted imaging modalities, nucleic acid aptamers have features such as superior recognition of structural epitopes and quick uptake in target cells. This explains the emergence of an evolved new class of aptamers into a wide spectrum of imaging applications over the last decade. Genetically encoded biosensors tagged with fluorescent RNA aptamers have been developed as intracellular imaging tools to understand cellular signaling and physiology in live cells. Cancer-specific aptamers labeled with fluorescence have been used for assessment of clinical tissue specimens. Aptamers conjugated with gold nanoparticles have been employed to develop innovative mass spectrometry tissue imaging. Also, use of chemically conjugated cancer-specific aptamers as probes for non-invasive and high-resolution imaging has been transformative for in vivo imaging in multiple cancers.

show abstract

“…This highlights its possible use for neurodegenerative diseases and brain delivery. This strategy is highly desirable due to the ability to directly modify microbubbles with different ligands and therapeutics, which when combined with more sensitive and tunable sonoporation techniques, leads to a very elegant and highly targeted technique (Ma et al, 2016;Xu et al, 2016). However, its inherent physical nature is a concern.…”

Section: U N C O R R E C T E D P R O O Fmentioning

confidence: 99%

Current Strategies for the Delivery of Therapeutic Proteins and Enzymes to Treat Brain Disorders

Duskey

Belletti

Pederzoli

et al. 2017

International Review of Neurobiology

View full text Add to dashboard Cite

Brain diseases and injuries are growing to be one of the most deadly and costly medical conditions in the world. Unfortunately, current treatments are incapable of ameliorating the symptoms let alone curing the diseases. Many brain diseases have been linked to a loss of function in a protein or enzyme, increasing research for improving their delivery. This is no easy task due to the delicate nature of proteins and enzymes in biological conditions, as well as the many barriers that exist in the body ranging from those in circulation to the more specific barriers to enter the brain. Several main techniques are being used (physical delivery, protein/enzyme conjugates, and nanoparticle delivery) to overcome these barriers and create new therapeutics. This review will cover recently published data and highlights the benefits and deficits of possible new protein or enzyme therapeutics for brain diseases.

show abstract

Biodegradable double-targeted PTX-mPEG-PLGA nanoparticles for ultrasound contrast enhanced imaging and antitumor therapy in vitro

Cited by 18 publications

References 22 publications

<p>G250 Antigen-Targeting Drug-Loaded Nanobubbles Combined with Ultrasound Targeted Nanobubble Destruction: A Potential Novel Treatment for Renal Cell Carcinoma</p>

<p>G250 Antigen-Targeting Drug-Loaded Nanobubbles Combined with Ultrasound Targeted Nanobubble Destruction: A Potential Novel Treatment for Renal Cell Carcinoma</p>

Targeted Molecular Imaging Using Aptamers in Cancer

Current Strategies for the Delivery of Therapeutic Proteins and Enzymes to Treat Brain Disorders

Contact Info

Product

Resources

About